News

Hemlibra is now the only prophylactic treatment for people with haemophilia A with and without factor VIII inhibitors that can be administered subcutaneously (under the skin) and at

Merck has announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to Delstrigo , a once-daily fixed-dose combination tablet of

Empagliflozin was evaluated for its efficacy, safety and tolerability as an adjunctive to insulin in comparison to placebo in the late-stage clinical program, dubbed EASE. The primary efficacy

ARO-HBV is the third generation subcutaneously administered RNA interference (RNAi) therapeutic of Arrowhead being developed as a potential curative therapy for patients with chronic HBV infection. The companies

In the ongoing study, Biktarvy was found to be statistically non-inferior to a regimen of abacavir/dolutegravir/lamivudine (600/50/300mg, ABC/DTG/3TC) through 96 weeks of therapy. The data will be presented

ALN-AAT02 is Alnylam’s first investigational RNAi therapeutic utilizing the Company’s enhanced stabilization chemistry plus (ESC+) GalNAc-conjugate technology. Alnylam ALN-AAT02 program lead vice president Thomas Hoock said: “We are

As per terms of the deal, Boston Pharmaceuticals purchased global rights to two complementary candidates targeting carbapenem-resistant enterobacteriaceae (CRE) and one candidate targeting Pseudomonas. The  anti-infective drug candidates

Kite and HiFiBiO intend to adapt HiFiBiO’s proprietary single cell technology platform to create a high throughput approach that will potentially allow for the in-depth screening of TCR

Kala Pharmaceuticals chairman, president and CEO Mark Iwicki said: “We are pleased to be partnering with Athyrium and to have their support and confidence in INVELTYS for the